tions for 222 domestically developed Class-1 new innovative drugs, while the figure
上海龙凤品茶微信s for 2017 were 402 and 181. Class-1 new drugs refer to drugs that have never been mark
eted in China or overseas, and innovative drugs means drugs with independent intellectual property rights.上海龙凤品茶微信
Among all the applications in 2018, 403 applications were for 198 drugs’ clinical trial approv
als, and 45 were for market approval for 24 drugs, while in 2017, 379 applications were for clinical trial appro
vals, involving 171 drugs, and 23 applications were for market approval, involving 10 drugs.
上海龙凤In 2018, 323 applications were for 115 chemical drugs, and 123 were for 106 biologics, while
in 2017, 324 applications were for 112 chemical drugs and 76 applications were for 68 biologics.
上海龙凤品茶微信Song Ruilin, executive president of the China Pharmaceutical Innovatio
n and Research Development Association, said Chinese pharmaceutical companies have ma
上海龙凤de remarkable progress in innovative drug research and development in the past few years,
especially in the area of biologics, thanks to their focus on innovation and homegrown R&D.
“In terms of pharmaceutical innovation, where we are now is completely different from where we were 15 years ago,” he said.上海龙凤
“Chinese companies used to focus on generics, but now they have been buil
ding up R&D capabilities and many invest generously in innovative drugs.”
上海龙凤品茶微信From 1949 to 2008, less than five domestically developed drugs were approved by Chine
se authorities, while from 2008 to 2018, the number increased by about 10 times to about 40, according to Song.上海龙凤
In 2018, nine Class-1 new drugs developed by domestic pharmaceutical companies wer
上海龙凤品茶微信e approved in China, figures from the National Medical Products Administration showed.
Most of the nine new drugs are treatments for cancer or rare diseases, or anti-virus therapies tha
t are urgently needed in medical practice, according to the National Medical Products Administration.
les to customers in the second quarter, where it predicted that an estima
ted loss would be “significantly” less than the $702 million lost in the first quarter.
The company delivered about 63,000 vehicles in the first quarter.
The gross profit margin on the Model 3 – a focus for investors – remained steady at 20 percent.
Tesla also announced it would start offering its own ins
urance product in about a month to better reflect the safety of its vehicles.
Tesla reported net loss attributable to common shareholders of $702.1 million, or $4.10 p
er share, in the first quarter ended March 31, compared with a loss of $709.6 million, or $4.19 per share, a year earlier.
Excluding some items, Tesla lost $1.77 per share, compared with
Wall Street expectations of a loss of 69 cents, according to data from Refinitiv.
showed that 160 million Chinese people have travel plans during the upcoming four-day May
Day holiday. Thailand, Japan, Vietnam, Taiwan and Indonesia are the top destinations outside the mainland.
Malaysia, which receives around 10 million Chinese tourists annua
lly, began to issue e-visas for Chinese in 2017. “The number of visa stickers on passports of Chinese
nationals dropped by 70 percent in the first year after the service was introduced, showing its high popularity,” said Han.
Since last year, countries including Australia, New Zealand, Singapore, Turkey, Thailand and Sr
i Lanka have started to accept visa application documents online and issue e-visas, either a bar code or QR code.
“When more countries that are mainstream travel destinations launch such services for Chinese, more will follow suit,” Dai said.